National Assembly is paying attention to news of AZ-Pfizer's

If the efficacy & safety of vaccines are confirmed, it will greatly affect domestic supply and demand and vaccination plans

Overseas studies have shown that the second shot of the Pfizer-Biontech vaccine after the first shot of the COVID-19 vaccine developed by AstraZeneca (AZ) and Oxford University is effective and safe.

 

The National Assembly also seems to be interested in responding to domestic quarantine authorities regarding cross-vaccination.

 

Based on overseas research results, The KCDA has decided to carry out research on cross-vaccination of COVID-19.

 

According to the multiple members of the National Assembly's Health and Welfare Committee on the 20th, quarantine authorities such as the KCDA will be asked about the possibility of cross-vaccination and future plans for the COVID-19 vaccine.

 

This is because overseas studies have shown that the immune effectiveness of AstraZeneca vaccine and Pfizer vaccine has been raised during the first and second cross-injections, respectively.

 

The Carlos III Health Institute said Monday that it had tested 670 people aged 18 to 59 who had been vaccinated against AstraZeneca and concluded that they were "very safe." In the group that was inoculated with Pfizer, the immune response increased 120 times a week later, and the same level of immunity was maintained in the group that was only the first inoculation with AstraZeneca vaccine.

 

Neutralizing antibodies that neutralize the COVID-19 increased seven times after the Pfizer vaccine.

 

The effectiveness is more than twice as high as that of the first and second vaccinations with AstraZeneca alone.

 

Only 1.7% reported side effects when cross-vaccinated with AstraZeneca and Pfizer vaccines.

 

Symptoms were mainly limited to headaches, muscle aches and fatigue, which were not serious, the researchers said.

 

If the cross-vaccination effect between the virus vector vaccine and the mRNA vaccine is proven, it will directly affect the plan and status of vaccination for COVID-19 in Korea.

 

This is why quarantine authorities, as well as the ruling and opposition parties of the National Assembly, are forced to react sensitively.

 

As overseas research results come out, domestic quarantine authorities are also stepping up efforts to check the efficacy and safety of cross-vaccines.

 

The KCDA said it was conducting a cross-vaccination study at the Korea National Institute of Health.

 

The main goal of the study was to establish additional vaccination plans for AstraZeneca inoculators.

 

The National Assembly is also expressing high interest in overseas research results and domestic research plans.

 

The domestic supply and demand rate of COVID-19 vaccine and inoculation rate have been the main issue between the ruling and opposition parties.

 

If effectiveness and safety are confirmed in cross-vaccination studies by quarantine authorities, the National Assembly will also be able to change or improve its national vaccination plan, which will change the focus of pending questions.

 

An official of the National Assembly's welfare committee said, "The government has already secured the amount of vaccines that all citizens will receive and has also set up a supply and demand plan." However, the U.S.

 

and others are reviewing various opinions every day on the need for booster shots or the amount of youth inoculation.

 

"The effect of cross vaccination is a variable that can greatly improve not only the global inoculation plan but also domestic supply and demand." Another member of the National Assembly said, "If cross-vaccination between virus vector Astra vaccine and mRNA vaccine does not have a big problem with efficacy and safety, and increases the effect, it will be good news now that "There is still a lack of evidence on cross-vaccination and quarantine authorities will check the status and direction."